PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35194103-1	2022	Human CYP2B6 enzyme although constitutes relatively low proportion (1-4%) of hepatic cytochrome P450 content, it is the major catalyst of metabolism of several clinically important drugs (efavirenz, cyclophosphamide, bupropion, methadone).	Bupropion	217-226	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-100	
34877801-1	2022	This study was designed to evaluate the effects of cenobamate, an antiseizure medication for focal seizures, on the pharmacokinetics (PK) of cytochrome P450 probes (bupropion, CYP2B6; midazolam, CYP3A4/5; warfarin, CYP2C9; omeprazole, CYP2C19) in healthy subjects.	Bupropion	165-174	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	141-156	
17082249-1	2007	BACKGROUND: CYP2B6 is a highly variable and polymorphic cytochrome P450 (CYP) enzyme involved in the biotransformation of an increasing number of drugs, including cyclophosphamide, bupropion, and the nonnucleosidic reverse transcriptase inhibitor efavirenz.	Bupropion	181-190	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-71	
27273149-0	2017	Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects.	Bupropion	101-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-82	
27387538-5	2016	Of the CYP enzymes tested, CYP2B6-catalyzed bupropion 6-hydroxylation was inhibited by S002-333 (IC50 ~ 9.25 +- 2.46 muM) in a stereoselective manner with (S)-isomer showing potent inhibition (IC50 ~ 5.28 +- 1.25 muM) in contrast to (R)-isomer which showed negligible inhibition on CYP2B6 activity (IC50 > 50 muM).	Bupropion	44-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	7-10	
17082249-1	2007	BACKGROUND: CYP2B6 is a highly variable and polymorphic cytochrome P450 (CYP) enzyme involved in the biotransformation of an increasing number of drugs, including cyclophosphamide, bupropion, and the nonnucleosidic reverse transcriptase inhibitor efavirenz.	Bupropion	181-190	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-15	
15769884-1	2005	The polymorphic human cytochrome P450 (P450) 2B6 is primarily responsible for the metabolism of several clinically relevant drugs including bupropion, cyclophosphamide, propofol, and efavirenz.	Bupropion	140-149	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-48	
14604466-2	2003	The possibility of cytochrome p450 (CYP) induction by bupropion (10 microM) was evaluated in-vitro by comparing catalytic activity, immunoreactive protein and CYP mRNA levels from human hepatocytes in primary culture versus cells treated with vehicle (0.5% methanol) and with rifampicin (rifampin) as a positive control.	Bupropion	54-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-34	
14604466-2	2003	The possibility of cytochrome p450 (CYP) induction by bupropion (10 microM) was evaluated in-vitro by comparing catalytic activity, immunoreactive protein and CYP mRNA levels from human hepatocytes in primary culture versus cells treated with vehicle (0.5% methanol) and with rifampicin (rifampin) as a positive control.	Bupropion	54-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39	
14604466-2	2003	The possibility of cytochrome p450 (CYP) induction by bupropion (10 microM) was evaluated in-vitro by comparing catalytic activity, immunoreactive protein and CYP mRNA levels from human hepatocytes in primary culture versus cells treated with vehicle (0.5% methanol) and with rifampicin (rifampin) as a positive control.	Bupropion	54-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	159-162